TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data TC BioPharm has reported a complete molecular response in a patient with Minimal Residual Disease after innovative gamma delta T cell therapy, marking a significant milestone.

TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data #United_Kingdom #Edinburgh #TC_BioPharm #TCB008 #Gamma_Delta_T_Cells

TC BioPharm Secures European Patent for Innovative T Cell Therapy Targeting Various Diseases TC BioPharm has announced the acquisition of a European patent for its advanced T cell therapies, targeting microbial, oncological, and viral diseases, enhancing their therapeutic applications.

TC BioPharm Secures European Patent for Innovative T Cell Therapy Targeting Various Diseases #United_Kingdom #Edinburgh #TC_BioPharm #Gamma_Delta_T_Cells #Patent_Rights

TC BioPharm Transitions from Nasdaq to OTC Markets Amid Company Changes TC BioPharm has announced its impending transition from Nasdaq to OTC Markets due to compliance issues. Despite challenges, the company is committed to advancing its innovative therapies.

TC BioPharm Transitions from Nasdaq to OTC Markets Amid Company Changes #NASDAQ #United_Kingdom #Edinburgh #TC_BioPharm #OTC_Markets

TC BioPharm Unveils Strategic Outsourcing To Streamline Operations and Boost Efficiency In a significant strategic move, TC BioPharm announces outsourcing initiatives to reduce operational costs, transitioning to a decentralized model to enhance efficiency.

TC BioPharm Unveils Strategic Outsourcing To Streamline Operations and Boost Efficiency #United_Kingdom #Edinburgh #TC_BioPharm #T_Cell_Therapy #Bryan_Kobel

TC BioPharm Plans Acquisition of Ophthalmic Pharma Company to Expand Glaucoma Treatment Portfolio TC BioPharm is set to acquire an innovative pharmaceutical company specializing in FDA-approved glaucoma treatments, strengthening its market position and revenue potential.

TC BioPharm Plans Acquisition of Ophthalmic Pharma Company to Expand Glaucoma Treatment Portfolio #United_Kingdom #pharmaceuticals #Edinburgh #TC_BioPharm #glaucoma

TC BioPharm's CEO to Share Insights on Cancer at European Forum Bryan Kobel, CEO of TC BioPharm, will participate in a critical cancer panel at the European Life Sciences CEO Forum, highlighting advancements in healthcare.

TC BioPharm's CEO to Share Insights on Cancer at European Forum #cancer_therapy #United_Kingdom #Edinburgh #TC_BioPharm #Bryan_Kobel

TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment TC BioPharm announces successful completion of Cohort A in the ACHIEVE clinical trial, showcasing promising results for TCB008 in treating AML.

TC BioPharm Completes Cohort A in ACHIEVE Clinical Trial for TCB008 Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial TC BioPharm celebrates a key achievement in its ACHIEVE trial by administering the initial doses to a patient in Cohort B, paving the way for innovative cancer therapies.

TC BioPharm Achieves Milestone with First Patient Dosing in ACHIEVE Trial #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008

TC BioPharm Announces Changes in ADS Ratio to Enhance Shareholder Value TC BioPharm has announced an update regarding its American Depositary Shares (ADS) ratio, aiming to improve shareholder value and trading dynamics in the market.

TC BioPharm Announces Changes in ADS Ratio to Enhance Shareholder Value #United_Kingdom #Edinburgh #ADS_Ratio #TC_BioPharm #glycolysis

TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches TC BioPharm announces intentions to initiate preclinical studies for TCB008, targeting H5N1, aimed at finding innovative treatments for the viral infection.

TC BioPharm Plans Groundbreaking Studies on H5N1 Treatment Approaches #United_Kingdom #Edinburgh #TC_BioPharm #TCB008 #H5N1

TC BioPharm Announces Participation in Sequire Investor Summit 2025 TC BioPharm will showcase its innovative T cell therapies at the Sequire Investor Summit in Puerto Rico, highlighting its clinical advancements.

TC BioPharm Announces Participation in Sequire Investor Summit 2025 #USA #San_Juan #TC_BioPharm #T_Cell_Therapy #Investor_Summit

The Unstoppable Rise of TC BioPharm on Nasdaq: A New Era in Immunotherapy TC BioPharm (NASDAQ: TCBP) continues to thrive in the biotech sector, trading steadily as it pioneers gamma-delta T cell therapies for cancer treatment.

The Unstoppable Rise of TC BioPharm on Nasdaq: A New Era in Immunotherapy #NASDAQ #United_Kingdom #Immunotherapy #Edinburgh #TC_BioPharm

TC BioPharm Reveals Strategic Approach to Acquisitions in Cell Therapy Market TC BioPharm outlines its ongoing acquisition strategy focusing on innovative therapies in cancer treatment, particularly in NK technologies and CAR-modified cells.

TC BioPharm Reveals Strategic Approach to Acquisitions in Cell Therapy Market #United_Kingdom #Edinburgh #TC_BioPharm #Cell_Therapy #CAR-NK

TC BioPharm Declares 25% Stock Dividend as It Eyes Growth in 2025 TC BioPharm has officially approved a 25% stock dividend for shareholders, signifying confidence in the company's financial growth in 2025.

TC BioPharm Declares 25% Stock Dividend as It Eyes Growth in 2025 #Stock_Dividend #United_Kingdom #Edinburgh #TC_BioPharm #gamma-delta_T_cells

TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients TC BioPharm announces completion of full-dose regimen in its ACHIEVE Phase 2b trial, with a strong safety profile and promising recruitment figures for 2025.

TC BioPharm's ACHIEVE Phase 2b Trial Completes Final Dosing for Patients #United_Kingdom #Clinical_Trial #Edinburgh #TC_BioPharm #TCB008

TC BioPharm Sets Date for Shareholder Meeting to Discuss Special Dividend Approval TC BioPharm announces a special meeting for shareholders to discuss a proposed dividend. Details inside about the date, amount, and more.

TC BioPharm Sets Date for Shareholder Meeting to Discuss Special Dividend Approval #Dividend #Shareholders #United_Kingdom #TC_BioPharm #Buckie

TC BioPharm Collaborates with CareDx for Groundbreaking Clinical Trial in Allogeneic Cell Therapy TC BioPharm has partnered with CareDx to enhance the ACHIEVE clinical trial, focusing on pharmacokinetic analysis of allogeneic cell therapy for AML.

TC BioPharm Collaborates with CareDx for Groundbreaking Clinical Trial in Allogeneic Cell Therapy #United_Kingdom #Edinburgh #TC_BioPharm #Achieve #CareDx

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment TC BioPharm provides a quarterly update on the ongoing ACHIEVE clinical trial, revealing positive safety data and plans for dose escalation of TCB008.

TC BioPharm Reports Progress on ACHIEVE Clinical Trial with Promising Safety Data for Cancer Treatment #United_Kingdom #Edinburgh #TC_BioPharm #ACHIEVE_Trial #TCB008